MA30161B1 - Combinaison pharmaceutique - Google Patents
Combinaison pharmaceutiqueInfo
- Publication number
- MA30161B1 MA30161B1 MA31114A MA31114A MA30161B1 MA 30161 B1 MA30161 B1 MA 30161B1 MA 31114 A MA31114 A MA 31114A MA 31114 A MA31114 A MA 31114A MA 30161 B1 MA30161 B1 MA 30161B1
- Authority
- MA
- Morocco
- Prior art keywords
- formulation
- combination
- pharmaceutical combination
- reverse transcriptase
- transcriptase inhibitor
- Prior art date
Links
- 238000009472 formulation Methods 0.000 abstract 3
- 239000000203 mixture Substances 0.000 abstract 3
- 229940122313 Nucleoside reverse transcriptase inhibitor Drugs 0.000 abstract 1
- 229940123527 Nucleotide reverse transcriptase inhibitor Drugs 0.000 abstract 1
- 238000002648 combination therapy Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 229940127557 pharmaceutical product Drugs 0.000 abstract 1
- 239000003419 rna directed dna polymerase inhibitor Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Une formulation pharmaceutique pour le traitement du VIH est fournie. La formulation est une combinaison d'un inhibiteur nucléosidique de la transcriptase inverse et d'un inhibiteur nucléotidique de la transcriptase inverse, dans laquelle formulation, la combinaison présente une stabilité augmentée par rapport aux thérapies de combinaison de la pratique précédente. L'invention fournit aussi un produit pharmaceutique contenant la formulation.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN1566MU2005 | 2005-12-14 | ||
IN1878MU2006 | 2006-11-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA30161B1 true MA30161B1 (fr) | 2009-01-02 |
Family
ID=38163276
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA31114A MA30161B1 (fr) | 2005-12-14 | 2008-07-11 | Combinaison pharmaceutique |
Country Status (15)
Country | Link |
---|---|
US (1) | US20080317852A1 (fr) |
EP (1) | EP2051703B1 (fr) |
JP (1) | JP5231242B2 (fr) |
KR (1) | KR20080091767A (fr) |
AP (1) | AP2008004533A0 (fr) |
AT (1) | ATE474560T1 (fr) |
AU (1) | AU2006325404B2 (fr) |
BR (1) | BRPI0620705A2 (fr) |
CA (1) | CA2633603C (fr) |
DE (1) | DE602006015721D1 (fr) |
MA (1) | MA30161B1 (fr) |
NZ (1) | NZ569349A (fr) |
RU (1) | RU2008128424A (fr) |
SI (1) | SI2051703T1 (fr) |
WO (1) | WO2007068934A2 (fr) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2004206821C1 (en) | 2003-01-14 | 2009-10-01 | Gilead Sciences, Inc. | Compositions and methods for combination antiviral therapy |
TWI375560B (en) | 2005-06-13 | 2012-11-01 | Gilead Sciences Inc | Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same |
TWI471145B (zh) | 2005-06-13 | 2015-02-01 | Bristol Myers Squibb & Gilead Sciences Llc | 單一式藥學劑量型 |
WO2009037449A1 (fr) * | 2007-09-18 | 2009-03-26 | Cipla Limited | Compositions pharmaceutiques solides comprenant un ou plusieurs inhibiteurs du virus de l'herpès et un ou plusieurs inhibiteurs de la transcriptase inverse |
GT200800303A (es) * | 2007-12-24 | 2009-09-18 | Combinacion anti-retroviral | |
WO2009106960A2 (fr) * | 2008-02-27 | 2009-09-03 | Aurobindo Pharma Limited | Compositions stables de lamivudine, de ténofovir et d'éfavirenz |
WO2009106954A1 (fr) * | 2008-02-27 | 2009-09-03 | Aurobindo Pharma Limited | Formes pharmaceutiques stables de lamivudine et de ténofovir |
MX2010011963A (es) | 2008-05-02 | 2010-12-06 | Gilead Sciences Inc | Uso de particulas trasportadoras solidas para mejorar la capacidad de procesamiento de un agente farmaceutico. |
KR101738325B1 (ko) * | 2009-02-06 | 2017-05-19 | 길리애드 사이언시즈, 인코포레이티드 | 조합 요법용 정제 |
WO2010125572A1 (fr) * | 2009-04-29 | 2010-11-04 | Hetero Research Foundation | Comprimés et capsules contenant de l'éfavirenz |
EP2435052B1 (fr) | 2009-05-27 | 2015-07-15 | Hetero Research Foundation | Formes pharmaceutiques solides de lamivudine s'administrant par voie orale avec isomalt |
EP2389929A1 (fr) * | 2010-05-30 | 2011-11-30 | Abdi Ibrahim Ilac Sanayi ve Ticaret Anonim Sirketi | Formulations pharmaceutiques de Ténofovir |
EP2579892A2 (fr) | 2010-06-09 | 2013-04-17 | Vaccine Technologies, Incorporated | Immunisation thérapeutique chez des patients infectés par le vih recevant un traitement antirétroviral stable |
PL2640362T5 (pl) | 2010-11-19 | 2022-05-02 | Gilead Sciences, Inc. | Kompozycje terapeutyczne zawierające hcl rylpiwiryny i fumaran dizoproksylu tenofowiru |
CA2835272A1 (fr) * | 2011-05-30 | 2012-12-06 | Cipla Limited | Composition pharmaceutique antiretrovirale |
CN103211826A (zh) * | 2013-05-14 | 2013-07-24 | 福建广生堂药业股份有限公司 | 一种抗病毒药物组合物及其制备方法和用途 |
EP2832351A1 (fr) * | 2013-07-29 | 2015-02-04 | Sanovel Ilac Sanayi ve Ticaret A.S. | Comprimé multicouche comprenant du tenofovir et de l'entecavir |
RU2660438C1 (ru) * | 2014-07-18 | 2018-07-06 | Джей ДаблЮ ФАРМАСЬЮТИКАЛ КОРПОРЭЙШН | Новая соль тенофовира дизопроксила |
CN104473896B (zh) * | 2014-12-01 | 2017-04-19 | 东莞市金美济药业有限公司 | 一种快速崩解的拉米夫定片及其制备工艺 |
ES2895951T3 (es) | 2015-12-02 | 2022-02-23 | Merck Sharp & Dohme | Composiciones farmacéuticas que contienen doravirina, fumarato de tenofovir disoproxil y lamivudina |
TR201617448A2 (tr) | 2016-11-29 | 2018-06-21 | Arven Ilac Sanayi Ve Ticaret Anonim Sirketi | Tenofovi̇r ve emtri̇si̇tabi̇n i̇çeren kati oral farmasöti̇k bi̇leşi̇mler |
CN106822155B (zh) * | 2016-12-29 | 2019-10-11 | 东北制药集团股份有限公司 | 依非韦伦、拉米夫定及富马酸替诺福韦酯三联复方片中片及其制备方法 |
RU2644156C1 (ru) | 2017-02-28 | 2018-02-08 | Александр Васильевич Иващенко | Пролекарство ингибитора NS5B HCV полимеразы, способ его получения и применения |
RU2662160C9 (ru) * | 2017-07-03 | 2018-10-22 | Александрович Иващенко Андрей | Комбинированный лекарственный препарат для терапии вирусных инфекций |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL108838C (fr) * | 1956-03-27 | |||
CS263951B1 (en) * | 1985-04-25 | 1989-05-12 | Antonin Holy | 9-(phosponylmethoxyalkyl)adenines and method of their preparation |
US5047407A (en) * | 1989-02-08 | 1991-09-10 | Iaf Biochem International, Inc. | 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties |
US5366972A (en) * | 1989-04-20 | 1994-11-22 | Boehringer Ingelheim Pharmaceuticals, Inc. | 5,11-dihydro-6H-dipyrido(3,2-B:2',3'-E)(1,4)diazepines and their use in the prevention or treatment of HIV infection |
US6057305A (en) * | 1992-08-05 | 2000-05-02 | Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic | Antiretroviral enantiomeric nucleotide analogs |
US5519021A (en) * | 1992-08-07 | 1996-05-21 | Merck & Co., Inc. | Benzoxazinones as inhibitors of HIV reverse transcriptase |
IT1264696B1 (it) * | 1993-07-09 | 1996-10-04 | Applied Pharma Res | Forme farmaceutiche destinate alla somministrazione orale in grado di rilasciare sostanze attive a velocita' controllata e differenziata |
US5922695A (en) * | 1996-07-26 | 1999-07-13 | Gilead Sciences, Inc. | Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability |
US5733788A (en) * | 1996-07-26 | 1998-03-31 | Gilead Sciences, Inc. | PMPA preparation |
US5935946A (en) * | 1997-07-25 | 1999-08-10 | Gilead Sciences, Inc. | Nucleotide analog composition and synthesis method |
UA72207C2 (uk) * | 1998-04-07 | 2005-02-15 | Брістол- Майєрс Сквібб Фарма Компані | Фармацевтична композиція ефавіренцу з добавкою дезінтегруючих агентів у вигляді швидкорозчинних капсул або таблеток та спосіб її виготовлення |
GB9820420D0 (en) * | 1998-09-18 | 1998-11-11 | Glaxo Group Ltd | Antiviral combinations |
ZA200110501B (en) * | 2001-05-11 | 2002-04-03 | Cipla Medpro Pty Ltd | Pharmaceutical composition. |
ZA200110499B (en) * | 2001-05-11 | 2002-04-03 | Cipla Medpro Pty Ltd | Pharmaceutical composition. |
MY169670A (en) * | 2003-09-03 | 2019-05-08 | Tibotec Pharm Ltd | Combinations of a pyrimidine containing nnrti with rt inhibitors |
HUP0500217A2 (hu) * | 2002-04-23 | 2005-06-28 | Lupin Limited | Tartós hatású, módosított hatóanyag-leadású mátrix készítmények |
US7462608B2 (en) * | 2002-04-26 | 2008-12-09 | Gilead Sciences, Inc. | Non nucleoside reverse transcriptase inhibitors |
US20050287177A1 (en) * | 2002-11-08 | 2005-12-29 | Glaxo Group Unlimited And Smithkline Beecham Corp. | Pharmaceutical compositions |
AU2004206821C1 (en) * | 2003-01-14 | 2009-10-01 | Gilead Sciences, Inc. | Compositions and methods for combination antiviral therapy |
US20050048112A1 (en) * | 2003-08-28 | 2005-03-03 | Jorg Breitenbach | Solid pharmaceutical dosage form |
TWI471145B (zh) * | 2005-06-13 | 2015-02-01 | Bristol Myers Squibb & Gilead Sciences Llc | 單一式藥學劑量型 |
WO2007013047A2 (fr) * | 2005-07-29 | 2007-02-01 | Ranbaxy Laboratories Limited | Compositions pharmaceutiques anti-retrovirales dispersibles dans l'eau |
-
2006
- 2006-12-14 US US12/097,387 patent/US20080317852A1/en not_active Abandoned
- 2006-12-14 AU AU2006325404A patent/AU2006325404B2/en not_active Ceased
- 2006-12-14 AT AT06820527T patent/ATE474560T1/de not_active IP Right Cessation
- 2006-12-14 AP AP2008004533A patent/AP2008004533A0/xx unknown
- 2006-12-14 JP JP2008545090A patent/JP5231242B2/ja active Active
- 2006-12-14 SI SI200630809T patent/SI2051703T1/sl unknown
- 2006-12-14 CA CA2633603A patent/CA2633603C/fr not_active Expired - Fee Related
- 2006-12-14 BR BRPI0620705-7A patent/BRPI0620705A2/pt not_active IP Right Cessation
- 2006-12-14 KR KR1020087016727A patent/KR20080091767A/ko not_active Application Discontinuation
- 2006-12-14 NZ NZ569349A patent/NZ569349A/en unknown
- 2006-12-14 EP EP06820527A patent/EP2051703B1/fr not_active Not-in-force
- 2006-12-14 DE DE602006015721T patent/DE602006015721D1/de active Active
- 2006-12-14 RU RU2008128424/15A patent/RU2008128424A/ru not_active Application Discontinuation
- 2006-12-14 WO PCT/GB2006/004687 patent/WO2007068934A2/fr active Application Filing
-
2008
- 2008-07-11 MA MA31114A patent/MA30161B1/fr unknown
Also Published As
Publication number | Publication date |
---|---|
AU2006325404A1 (en) | 2007-06-21 |
DE602006015721D1 (de) | 2010-09-02 |
CA2633603A1 (fr) | 2007-06-21 |
AU2006325404B2 (en) | 2012-03-01 |
KR20080091767A (ko) | 2008-10-14 |
CA2633603C (fr) | 2016-09-13 |
AP2008004533A0 (en) | 2008-08-31 |
SI2051703T1 (sl) | 2011-01-31 |
US20080317852A1 (en) | 2008-12-25 |
BRPI0620705A2 (pt) | 2011-11-22 |
WO2007068934A3 (fr) | 2008-02-21 |
EP2051703A2 (fr) | 2009-04-29 |
WO2007068934A2 (fr) | 2007-06-21 |
JP2009519311A (ja) | 2009-05-14 |
NZ569349A (en) | 2012-01-12 |
RU2008128424A (ru) | 2010-01-20 |
JP5231242B2 (ja) | 2013-07-10 |
ATE474560T1 (de) | 2010-08-15 |
EP2051703B1 (fr) | 2010-07-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA30161B1 (fr) | Combinaison pharmaceutique | |
ATE443043T1 (de) | Phenylcarboxamide als beta-sekretase-hemmer zur behandlung von alzheimer | |
MA31183B1 (fr) | Inhibiteurs de mek | |
TNSN01145A1 (fr) | Derives d'imidazole a noyau aryle ou heteroaryle condense, et compositions les contenant. | |
CL2004002061A1 (es) | Compuestos derivados de heterociclos condensados que contienen nitrogeno; composicion farmaceutica; y su uso como agente antiviral, inhubidor de integrasa y como agente anti-vih. | |
ATE395912T1 (de) | Dipeptidylpeptidase-hemmer für die behandlung oder prävention von diabetes | |
DE60330485D1 (de) | Zur behandlung von diabetes | |
MA27556A1 (fr) | Derives de phenylalanine comme inhibiteurs de la dipeptidyl peptidase pour le traitement ou la prevention du diabete | |
MA27347A1 (fr) | Inhibiteurs de protease du vih, compositions les contenant, leurs utilisations pharmaceutiques et matieres pour leur synthese | |
ATE447574T1 (de) | 3-amino-4-phenylbutansäurederivate als dipeptidylpeptidase-hemmer zur behandlung oder vorbeugung von diabetes | |
TNSN06386A1 (fr) | Derives de tetraazabenzo [e] azulene et leurs analogues | |
TNSN06109A1 (fr) | Derives [3.1.0] bicycliques servant d'inhibiteurs du transporteur de glycine | |
RS20110578A2 (en) | MACROCYCLIC CARBOXYLIC ACIDS AND ACYLSULPHONAMIDES AS HCV REPLICATION INHIBITORS | |
WO2000047553A8 (fr) | COMPOSES ALCENYLE ET ALKYNYLE INHIBITEURS DU FACTEUR Xa | |
TNSN00121A1 (fr) | Composes nouveaux inhibiteurs de metalloproteases, procede pour leur preparation et compositions pharmaceutiques les contenant | |
BR0309557A (pt) | Inibidores da transcriptase reversa não nucleosìdeos | |
TNSN01102A1 (fr) | Derives de pyrazole nouveaux, procede pour leur preparation et compositions les contenant. | |
MA34559B1 (fr) | Formulation pour le traitement du cancer | |
MX2010002296A (es) | Inhibidores iv de polimerasa de fosfadiazina hcv. | |
TNSN01114A1 (fr) | Derives d'imidazole nouveaux et compositions les contenant | |
TNSN06370A1 (fr) | Derives de pyrimidine pour le traitement d'une croissance cellulaire anormale | |
BRPI0418384A (pt) | composições farmacêuticas e métodos referentes à inibição de adesões fibrosas utilizando diversos agentes | |
BRPI0513051A (pt) | combinação de inibidores de transcriptase reversa e de protease anti-hiv | |
TNSN99001A1 (fr) | Indoles 2,3-substitues servant d'agents anti-inflammatoires et analgesiques | |
ATE466595T1 (de) | Verbindungen und methoden für das downregulating der effekte von tgf-beta |